Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Gynecologic 4Classical hematology 4Myeloid 3Genitourinary 3Thoracic 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Smoking Cessation 1Motor Activity 1Lung Neoplasms 1Inflammation 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Aspirin × Thoracic × 1 year × Clear all
NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting
2,000 enrolled
Thoracic

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

NCT04184921 2026-02-03

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Completed
216 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡